Testimony Before the FDA’s Peripheral and Central Nervous System Drugs Advisory Committee Regarding Lecanemab for the Treatment of Alzheimer’s Disease
In testimony before the Food and Drug Administration’s (FDA’s) Peripheral and Central Nervous System Drugs Advisory Committee, Public Citizen urged the committee to recommend that the FDA not approve the supplemental biologics license application for lecanemab for the treatment of Alzheimer’s disease, because the evidence for the drug’s benefits does not outweigh its significant risks.